Correction: A previous version of this story incorrectly listed an associate not actually on the deal for Latham & Watkins. Alexander Berg did not work on the deal, instead it is Alexander White, out of the Menlo Park office.
SAN FRANCISCO — Latham & Watkins advised Menlo Park-based Avalanche Biotechnologies Inc. in filing its initial public offering. The clinical stage biotechnology firm listed 6 million shares of common stock at $17 a share on July 31, looking to raise $102 million.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
